Free shipping on all orders over $ 500

Mavorixafor

Cat. No. M6217

All AbMole products are for research use only, cannot be used for human consumption.

Mavorixafor Structure
Synonym:

AMD-070; AMD-11070

Size Price Availability Quantity
5mg USD 150  USD150 In stock
10mg USD 230  USD230 In stock
25mg USD 415  USD415 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Mavorixafor (AMD-070) is a potent and selective antagonist of CXCR4 with an IC50 value of 13 nM in a CXCR4 125I-SDF inhibition binding assay, and inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs.

In vitro: AMD-070 is confirmed against X4 strain of HIV-1, HIV-1 IIIb in MT-4 cells, and The IC50 values for AMD-070 are 9-fold higher (0.009 μM vs 0.001 μM) and 8.7-fold higher (0.003 μM vs 0.026 μM) in PBMCs compared to MT-4 cells. AMD-070 has antiviral ability with the IC50 value of 15.5 nM.

In vivo: AMD-070 (2.5 mg/kg, i.v.) shows promising oral bioavailability in rat and dog. The rate of clearance is species dependent with AMD-070 having lower clearance in dog compared to rat.

Customer Product Validations & Biological Datas
Source PLoS One (2016). Figure 5. AMD-070
Method IP injections
Cell Lines murine model of pulmonary fibrosis
Concentrations 400 μg/animal
Incubation Time 24 h
Results When lungs were stained with Masson’s Trichrome stains, there was an average value of 3.7% (SEM ± 1.1) lung fibrosis in the BLM plus acetate buffer control; 10.5% (SEM ±2.5) in the BLM plus AMD070 and 0% (n = 10) in the PBS plus acetate buffer groups respectively
Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models C57BL/6 mice
Formulation PBS
Dosages 50 mg/kg
Administration i.p.
Chemical Information
Molecular Weight 349.47
Formula C21H27N5
CAS Number 558447-26-0
Solubility (25°C) 10 mM in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Chow LN, et al. PLoS One. Impact of a CXCL12/CXCR4 Antagonist in Bleomycin (BLM) Induced Pulmonary Fibrosis and Carbon Tetrachloride (CCl4) Induced Hepatic Fibrosis in Mice.

[2] Zhang C, et al. Chem Biol Drug Des. Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.

Related CXCR Products
Elubrixin

Elubrixin (SB-656933) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

VUF 11222 

VUF 11222 is a CXCR3 non-peptide-like agonist.

(±)-AMG 487 

(±)-AMG 487 is a racemate of AMG 487.

Elubrixin tosylate

Elubrixin tosylate (SB-656933 tosylate) is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

Elubrixin hydrochloride

Elubrixin (SB-656933) hydrochloride is a potent, selective, competitive, reversible and orally active CXCR2 antagonist and an IL-8 receptor antagonist.

  Catalog
Abmole Inhibitor Catalog




Keywords: Mavorixafor, AMD-070; AMD-11070 supplier, CXCR, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.